Expertos Invitados





TUBERCULOSIS EXTENSAMENTE RESISTENTE EN LA ARGENTINA. NUESTRA EXPERIENCIA

(especial para SIIC © Derechos reservados)
La información sobre seguridad, tolerabilidad y eficacia acerca de drogas potencialmente útiles en el tratamiento de la tuberculosis extensamente resistente es de extrema utilidad, no sólo para mejorar el pronóstico individual de estos pacientes sino también para controlar su diseminación.
abbate9_82710.jpg Autor:
Eduardo Abbate
Columnista Experto de SIIC

Institución:
Hospital de Enfermedades Infecciosas Francisco J Muñiz

Artículos publicados por Eduardo Abbate
Coautores
Marisa Vescovo* Mónica Cufré* Marcela Natiello** Ana García** Pablo González Montaner*** 
Médica, Hospital de Enfermedades Infecciosas Francisco J Muñiz, Buenos Aires, Argentina*
Médica, Instituto de Tisioneumonología "Prof.Dr.R.Vaccareza", Buenos Aires, Argentina**
Médico, Instituto de Tisioneumonología "Prof.Dr.R.Vaccareza", Buenos Aires, Argentina***
Recepción del artículo
28 de Junio, 2010 		Aprobación
30 de Agosto, 2010
Primera edición
14 de Septiembre, 2010 		Segunda edición, ampliada y corregida
7 de Junio, 2021

TUBERCULOSIS EXTENSAMENTE RESISTENTE EN LA ARGENTINA. NUESTRA EXPERIENCIA

Resumen
La tuberculosis extensamente resistente a múltiples drogas (XDR-TB) (resistente a isoniacida, rifampicina, alguna fluoroquinolona y al menos una entre kanamicina, amikacina o capreomicina), ha sido descrita en la mayoría de las regiones del mundo con efectos devastadores. Por esta razón, la información sobre seguridad, tolerabilidad y eficacia acerca de drogas potencialmente útiles en su tratamiento es de extrema utilidad, no sólo para mejorar el pronóstico individual de estos pacientes sino también para controlar su diseminación. Se presentan 18 casos de localización pulmonar en pacientes sin sida. Se trataron con esquemas que incluyeron en todos los casos linezolida; en 13, moxifloxacina, y en 13, tioridazina, todos negativizaron al examen directo y cultivo del esputo. Once pacientes cumplieron criterios de curación, 6 están aún en tratamiento y 3 abandonaron. Diez pacientes presentaron efectos adversos, en sólo 1 caso debió suspenderse la tioridazina. La utilización de linezolid, moxifloxacina y tioridazina ha contribuido a la evolución satisfactoria de estos pacientes. Estos fármacos son considerados de utilidad en esta serie, pero deben ser empleados en centros especializados con experiencia en el manejo de la XDR-TB.

Palabras clave
tuberculosis, Mycobacterium tuberculosis, tuberculosis multirresistente, tuberculosis extensamente resistente, XDR-TB


Artículo completo
(castellano)
Extensión:  +/-6.32 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Extensively drug-resistant tuberculosis in Argentina. Our experience

Abstract
Drug-resistant tuberculosis (XDR-TB), defined as the resistance to rifampin and isoniacid plus resistance to any fluoroquinolone and at least one second-line injectable drug (amikacin, kanamycin and capreomycin), has been reported in most regions of the world and poses a new threat to TB control worldwide. Thus, information on safety, tolerability and efficacy of other drugs potentially useful in the treatment of these cases is urgent to improve individual outcomes and control the spread of XDR-TB. We describe the management and treatment outcomes of 18 cases of pulmonary XDR-TB in non-AIDS patients. All patients received daily-supervised therapy with an average of 4 drugs for which their susceptibility had been documented. These schemes included linezolid in 18, moxifloxacin in 13 and thioridazine in 13. All patients became negative to sputum and culture. Eleven patients fulfilled cure criteria, 6 are still in treatment and 3 abandoned the therapy. Long term therapy was well tolerated in most patients, ten presented adverse side effects, and, for these reasons thioridazine was stopped in one patient. Linezolid, moxifloxacyn and thioridazine contributed to the satisfactory evolution of our patients. These drugs were considered useful in the reported cases and should be used in specialized centres with experience in the management of XDR-TB.

Key words
tuberculosis, Mycobacterium tuberculosis, multidrug-resistant tuberculosis, extensively drug-resistant tuberculosis, XDR-TB

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Diagnóstico por Laboratorio, Neumonología
Relacionadas: Administración Hospitalaria, Bioquímica, Epidemiología, Farmacología, Infectología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 6.32 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Eduardo Abbate, Instituto de Tisioneumonología "Prof. Dr. R. Vaccareza" , 1281, Av. Vélez Sarsfield 405, Buenos Aires, Argentina
Patrocinio y reconocimiento:
Agradecimiento: Los autores expresan su agradecimiento por la inestimable colaboración al personal del laboratorio "A. Cetrángolo" del Hospital F. J. Muñiz, Instituto de Tisioneumonología "Prof. Dr .R. Vaccareza" (Jefa: Dra. Marta Ambroggi) y de Micobacterias, Instituto Nacional de Enfermedades Infecciosas "C. G. Malbrán" (Dra. Lucía Barrera, Dra. Viviana Ritacco y Dr. Norberto Simboli) cuya valiosa tarea nos permite el manejo clínico racional de la XDR-TB.
Bibliografía del artículo


1. World Health Organization. WHO Factsheet Number 310: The 10 leading causes of death by broad income Group (2004). Geneva, World Health Organization, 2008.
2. World Health Organization. Global Tuberculosis Control: surveillance, planning, financing: WHO Report 2008, Geneva. World Health Organization, 2008.
3. Edlin BR, Tokars JL, Grieco MH y col. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. New Eng J Med 326:1514-21, 1992.
4. Breathnach AS, De Ruiter A, Holdsworth GM, y col. An outbreak of multidrug-Resistant tuberculosis in a London teaching hospital. J Hosp Infect 39:111-17, 1998.
5. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 33:1085-1094, 2009.
6. Zignol M, Hosseini MR, Wright A, y col. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194:479-85, 2006.
7. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Weekly Epidemiol Record 81:430-32, 2006.
8. Gandhi NR, Moll A, Sturm AW, y col. Extensively drug-resistant tuberculosis as a cause of death in a patient coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-80, 2006.
9. Mitnick CD, Shin SS, Seung KJ, y col. Comprehensive treatment of extensively drug-resistant tuberculosis. N Eng J Med 359:563-74, 2008.
10. Centers for Diseases Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs world-wide. MMWR Morb Mort Wkly Rep 55:301-05, 2006.
11. Blass SH, Mutterlein R, Weig J, y col. Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect Dis 8:60-67, 2008.
12. Velayati AA, Masjedi MR, Farnia P, y col. Emergenge of new forms of totally drug-resistant tuberculosis bacilli. Chest 136:420-25, 2009.
13. Laserson KP, Thorpe LE, Leimane V, y col. Speaking the same language: treatment outcomes definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9:640-45, 2005.
14. Siddigi SH, Libonati JP, Middlebrook G. Evaluation of a rapid radiometric for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 13:908-12, 1981.
15. Wayne LG. Simple pyrazinamidasa and ureasa test for routine identificaction of Mycobactaria. Am Rev Respir Dis 109:147-31, 1974.
16. Canetti G, Rist N, Grosset J. Mesure de la sensibilité du bacilli tuberculleux aux drogues antibacillaires pour la méthode des proportions. Rev de Tuberculose 27:217-72, 1963.
17. Guidelines for drug susceptibility testing for second line anti tuberculosis drugs for DOTS-PLUS. WHO/CDS/TB 2001.288.
18. Van Embden JDA, Cave MD, Crawford JT, y col. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting : recommendations for a standardized methodology. J Clin Microbiol 31:406-09, 1993.
19. Ritacco V, Di Lonardo M, Reniero A, y col. Nosocomial spread of HIV-related Multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 176:637-42, 1997.
20. Raviglione MC, Smith IM. XDR tuberculosis. Implications for global public health. N Engl J Med 356:1554-56, 2007.
21. Van Rie A, Enarson D. XDR tuberculosis: an indicator of public health negligent. Lancet 368:1554-56, 2006.
22. Blower S, Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect Dis 7:443, 2007.
23. Van Helden PD, Victor T, Warren RM. The "source" of drug resistant TB outbreaks (letter). Science 314:419-20, 2006.
24. Mukherjee J, Rich ML, Socci AR, y col. Programmes and principles in treatment of Multidrug-resistant tuberculosis. Lancet 363:474-81, 2004.
25. Shah NS, Wright A, Bai GH, y col. Worldwide emergence of extensively drug- resistant tuberculosis. Emerg Infect Dis 13:380-87, 2007.
26. Ballow CH, Jones RN, Biedenbach DJ, y col. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 43:75-83, 2002.
27. Alcalá L, Ruiz-Serrano MJ, Pérez Fernández Turégano C, y col. In vitro activities of linezolid against clinical isolates of Mycobaterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 47:416-17, 2003.
28. Fortun J, Martin-Davila P, Navas E, y col. Linezolid for the treatment of multidrug- Resistant tuberculosis. J Antimicrob Chemoter 56:180-85, 2005.
29. Valencia ME, Moreno V, Laguna F, y col. Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities? Enferm Infecc Microbiol Clin 19:37-39, 2001.
30. World Health Organization. Guidelines for the programmatic management of drug- resistant tuberculosis. WHO/HTM/TB/2006.361. Emergency update 2008. Executive summary (leaflet available requesting to: tbdocs@who.int).
31. Abbate E, Brea A, Cufré M, y col. Linezolid in multidrug-resistant tuberculosis treatment. Eur Respir J 24(Supppl.48):485s, 2004.
32. Abbate E, Brea A, Cufré M, y col. Linezolid en el tratamiento de tuberculosis multirresistente. Archiv Bronconeum; 40(Suppl.4): 26, 2004.
33. Gerson SL, Kaplan SL, Bruss JB, y col. Hematologic effects of linezolid: summary of clinical experience. Antimicrb Agents Chemother 46:2723-26, 2002.
34. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 285:1291, 2001.
35. Acha V, Zaragueta M, Martinez Y, y col. Linezolid induced anemia. Enferm Infecc Microbiol Clin 21:321-22, 2003.
36. Bressler AM, Zimmer SM, Gilmore JL, y col. Peripheral neuropathy associated with prolonged used of linezolid. Lancet Infec Dis 4:528-31, 2004.
37. Lee E, Burger S, Shah J, y col. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 37:1389-91, 2003.
38. Migliori GB, Eker B, Richardson MD, y col. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 34:387-93, 2009.
39. Schecter GF, Scott C, True L, y col. Linezolid in the treatment of multidrug- resistant tuberculosis. Clin Infect Dis 50:49-55, 2010.
40. Condos R, Hadgiangelis N, Leibert E, y col. Case series report of a linezolid- containing regimen for extensively drug-resistant tuberculosis. Chest 134:187-92, 2008.
41. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR-and XDR-TB: an Indian perspective (letter). Eur Respir J 35:936-38, 2010.
42. Migliori GB, Eker B, Richardson MD y col. (Letter response). Eur Respir J 35:938-40, 2010.
43. Koh WJ, Kwon OJ, Gwak H, y col. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64:388-91, 2009.
44. Lienhardt Ch, Vernon A, Raviglione MC. New drugs regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine 16:186-93, 2010.
45. Gillespie SH, Kennedy N. Fluoroquinolones a new treatment for tuberculosis. Int J Tuberc Lung Dis 2:265-71, 1998.
46. Rodríguez JC, Ruiz M, Climent A, y col. In Vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 17:229-31, 2001.
47. Ji B, Lounis N, Maslo C, y col. In vitro and in vivo activities of moxifloxacin and clinafoxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:2066-69, 1998.
48. Hu Y, Coates AR, Mitchinson DA. Sterilizing activity of fluoroquinolones against Rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:653-57, 2003.
49. Devasia RA, Blackman A, Gebretsadik T, y col. Fluoroquinolone resistance in Mycobacterium tuberculosis. Am J Respir Crit Care Med 180:365-70, 2009.
50. Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother 40:319-27, 1997.
51. Bettencourt MV, Bosne-David S, Amaral L. Comparative in vitro activity of phenothiazines against multi-drug resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 16:69-71, 2000.
52. Amaral L, Viveiros M, Kristiansen JE. Non antibiotics: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 7:887-91, 2006.
53. Thacoody HKR. Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol 64:566-574.
54. The WHO/IUATLD Global Project on antituberculosis drug resistance surveillance Anti-tuberculosis drug resistance in the world. Fourth Global Report. WHO/ HTM/TB 2008.394.
55. Abbate E, Vescovo M, Natiello M, y col. Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacables epidemiológicos, bacteriológicos, terapéuticos y evolutivos. Rev Arg Med Respir 7:19-25, 2007.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008